Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-927 and ABBV-181 in advanced solid tumors
NCT02988960Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2017
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of giloralimab in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (9 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Tolerated Dose or Recommended Phase 2 Dose at 8 weeks, Time to Maximum Concentration at 12 weeks and 5 more. Started Feb 2017; status: active, not recruiting.
02
Drugs
giloralimab
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02988960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988960.